Segmental Reporting

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Segment Reporting Disclosure

20.       SegmentReporting

Shire operates as one operating and reportable segment engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs.

For a more detailed description of segment disclosures about products, geographic areas and major customers, please read Note 23, Segment Reporting, of the Company's Annual Report on Form 10-K for the year ended December 31, 2015.

In the periods set out below, revenues by major product were as follows:

	3 Months Ended March 31,
	2016	2015
	$’M	$’M
	___________	___________
VYVANSE	509.2	416.8
LIALDA/MEZAVANT	168.0	148.5
CINRYZE	164.2	148.1
FIRAZYR	128.3	92.5
ELAPRASE	123.6	125.0
REPLAGAL	103.2	97.5
ADDERALL XR	98.8	95.7
VPRIV	83.6	86.4
PENTASA	64.0	78.7
GATTEX/REVESTIVE	51.7	14.9
FOSRENOL	37.7	44.1
XAGRID	28.3	25.3
NATPARA	15.6	-
KALBITOR	10.4	-
INTUNIV	10.2	17.4
Other product sales	30.5	32.3
	____________	____________
Total product sales	1,627.3	1,423.2
	____________	____________